UW lab spinoff focused on AI-enabled protein design cancer treatments

Paige Browning

John O'Brien

September 12, 2025 / 7:24 pm

A Seattle startup company has inked a deal with Eli Lilly to develop AI powered cancer treatments. The team at Lila Biologics says they're pioneering the translation of AI design proteins for therapeutic applications. Anindya Roy is the company's co-founder and chief scientist. He told KUOW’s Paige Browning about their work.

This interview has been edited for clarity.

Paige Browning : Tell us about Lila Biologics. You spun out of UW Professor David Baker's protein design lab. What's Lila's origin story?

Anindya Roy : I moved to David Baker's group as a postdoctoral scientist, where I was working on some of the molecules that we are currently developin

See Full Page